| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 116801 | 25 tests | $130 | ||
| 116802 | 100 tests | $295 |
| Clone | Lintuzumab |
|---|---|
| Application | Flow Cytometry |
| Reactivity | Human |
| Format | iF647 |
| Target Name | CD33, Siglec-3, gp67, p67, Siglec3 |
| Isotype | Human IgG1 |
| Antibody Type | Monoclonal |
| Regulatory Status | RUO |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA |
| Protein Concentration | Supplied at a lot-specific concentration. |
| Storage&Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Recommended Usage | For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. iF647 has an excitation max at 656 nm and an emission max at 670 nm. |
| Excitation Laser | Red Laser (633 nm) |
| See All Formats | Clone Lintuzumab |
Human CD33 is a sialic acid–binding immunoglobulin-like lectin (Siglec-3) expressed primarily on myeloid lineage cells, including monocytes, myeloid progenitors, and some dendritic cells. It functions as an inhibitory receptor that modulates immune cell activation through intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Structurally, CD33 is a type I transmembrane glycoprotein composed of an extracellular domain with Ig-like folds that bind sialylated glycans, a single transmembrane region, and a cytoplasmic tail containing signaling motifs. Its ligands are sialic acid–containing glycoproteins and glycolipids commonly found on cell surfaces, enabling it to regulate cell–cell interactions and dampen immune responses.
CD33 is highly relevant in disease, particularly in acute myeloid leukemia (AML), where it is overexpressed on leukemic blasts, making it a valuable diagnostic marker and therapeutic target. Lintuzumab is a humanized monoclonal antibody directed against CD33 that binds the extracellular domain and promotes immune-mediated cytotoxicity, including antibody-dependent cellular cytotoxicity (ADCC). Although unconjugated lintuzumab has shown modest efficacy, it has been explored in combination therapies and as a targeting moiety for antibody-drug conjugates or radioimmunotherapy. Targeting CD33 allows selective elimination of malignant myeloid cells while sparing non-myeloid tissues, positioning CD33-directed agents, including lintuzumab-based strategies, as important components in AML therapeutic development.
iF647 Human IgG1 Isotype Control Antibody
iF647 Anti-Human CD33 Antibody TDS
Have a product or application question? Consult our FAQs or contact us.
